Can Dendreon Turn It On?

The biotech's stock, down almost 80% since last year, plunged Tuesday after the maker of Provenge announced another quarterly loss.

Shares of Dendreon (ticker: DNDN), which is focused on cancer treatments, sank 22%, or $2.63, to $9.05 on Tuesday afternoon after the biotech company lowered its outlook and reported another quarterly loss of $103.9 million, or 70 cents per share, albeit better than the loss of $112.8 million, or 78 cents...